(NASDAQ: UPB) Upstream Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.32%.
Upstream Bio's earnings in 2026 is -$156,764,000.On average, 9 Wall Street analysts forecast UPB's earnings for 2026 to be -$160,680,451, with the lowest UPB earnings forecast at -$179,727,446, and the highest UPB earnings forecast at -$137,709,775. On average, 7 Wall Street analysts forecast UPB's earnings for 2027 to be -$163,657,224, with the lowest UPB earnings forecast at -$187,727,184, and the highest UPB earnings forecast at -$138,281,184.
In 2028, UPB is forecast to generate -$195,122,860 in earnings, with the lowest earnings forecast at -$212,793,029 and the highest earnings forecast at -$164,566,038.